logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma

Feb 13, 2024•almost 2 years ago

Amount Raised

$75 Million

Round Type

series a

Chapel HillBiotechnology

Investors

Population Health PartnersMaverick CapitalSanofiSaturn PartnersArch Venture PartnersGvAccess BiotechnologyBain Capital Life SciencesMarshall WaceViking Global Investors

Description

Areteia Therapeutics announced an additional $75 million in Series A financing to support the expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma.

Company Information

Company

Areteia Therapeutics

Location

Chapel Hill, North Carolina, United States

About

Areteia Therapeutics, Inc. is a biotech company focused on advancing the Phase III program for dexpramipexol, the first potential oral medication for eosinophilic asthma.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech